Heplisav is an investigational adult hepatitis B vaccine, which in earlier Phase 3 trials, showed increased, rapid protection with fewer doses than current licensed vaccines.
Both the studies showed that Heplisav provides faster, more and longer-lasting immunity in persons with diabetes than the vaccine, Engerix-B.
The trial enrolled 218 subjects with diabetes of which 179 were administered with Heplisav and 39 with Engerix-B.
The seroprotection rates (SPRs) for Heplisav were superior over Engerix-B at weeks 8 through 52.